Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Glenmark launches...

    Glenmark launches measurable inhaler for asthma, COPD patients

    Written by savita thakur thakur Published On 2016-05-26T14:16:13+05:30  |  Updated On 26 May 2016 2:16 PM IST
    Glenmark launches measurable inhaler for asthma, COPD patients

    Pharmaceutical major Glenmark launched an inhaler for asthma and Chronic Obstructive Pulmonary Disease (COPD) patients that displays the medicine dose remaining in it.


    "Digital dose inhaler or 'Digihaler' will enable the patients to track the number of doses that have been consumed. This will further enable the doctors to determine patient's adherence to the prescribed therapy regime," said Glenmark president Sujesh Vasudevan.


    Priced in the range of Rs.300 to Rs.450, the Digihaler comes with a small screen which displays the number of puffs remaining, discounting from 120, the typical number of medicine puffs a standard inhaler offers.


    "Conventional inhalers known as metered dose inhalers give no clue of the remaining amount of medicine once they are opened for use, giving room for error in adherence to the therapy regimen," said Vasudevan.


    He further said that a Digihaler proves more effective in addressing pseudo-adherence and tail-off phenomenon.


    "Pseudo-adherence is when patients think that he is taking the medication but in reality is just activating a nearly empty canister. A tail-off phenomenon occurs when patients continue to use inhaler beyond the recommended number of doses," said Vasudevan.


    Digihaler's other benefits include giving warning about the impending exhaustion of the medicine and when the medicine finishes.


    The digital dose inhaler falls in the respiratory category of Glenmark portfolio of products which contributes 15-16 percent of its business in India.


    According to Vasudevan, the Indian inhaler market is Rs.500 crore big into which Digihaler is making its debut as the first digital dose inhaler.


    The newest product from the pharma major will be manufactured in Baddi in Himachal Pradesh and Aurangabad in Maharashtra.

    asthmaChronic Obstructive Pulmonary DiseaseCOPDDigihalerGlenmarkGlenmark Pharmaceuticalsinhaler

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    savita thakur thakur
    savita thakur thakur
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok